Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria - Wikidata - awgldk - TriplyDB

Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria

Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria

http://www.wikidata.org/entity/Q33665436

about

Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives New treatment options for late Na current, arrhythmias, and diastolic dysfunction Atrial Heterogeneity Generates Re-entrant Substrate during Atrial Fibrillation and Anti-arrhythmic Drug Action: Mechanistic Insights from Canine Atrial Models Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure.Current and emerging antiarrhythmic drug therapy for ventricular tachycardia Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation.Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations Electrophysiologic basis for the antiarrhythmic actions of ranolazine.Novel pharmacological targets for the rhythm control management of atrial fibrillation.Current issues in atrial fibrillation.Novel anti-arrhythmic medications in the treatment of atrial fibrillation Atrial arrhythmogenicity of KCNJ2 mutations in short QT syndrome: Insights from virtual human atria.Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation.Role of late sodium channel current block in the management of atrial fibrillation.The Effects of Ranolazine on Paroxysmal Atrial Fibrillation in Patients with Coronary Artery Disease: A Preliminary Observational Study.New developments in atrial antiarrhythmic drug therapy.Mechanisms of termination and prevention of atrial fibrillation by drug therapy.Ranolazine: an antianginal drug with antiarrhythmic properties.Stable angina pectoris: antianginal therapies and future directions.New directions in antiarrhythmic drug therapy for atrial fibrillation.Ranolazine: clinical applications and therapeutic basis.Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation.Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications.Ranolazine for the treatment of atrial fibrillation.Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis.Novel ion channel targets in atrial fibrillation.The Significance of the Late Na+ Current for Arrhythmia Induction and the Therapeutic Antiarrhythmic Potential of Ranolazine.Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization.Antiarrhythmic Drug Therapy for Rhythm Control in Atrial Fibrillation.Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodarone-Only Therapy.Antiarrhythmic properties of ranolazine--from bench to bedside.Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.Advances in the Pharmacologic Management of Atrial Fibrillation.Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation.Atrial selectivity in Na+channel blockade by acute amiodarone.Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin.Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.

P2860

Q24601144-281D3FCC-E4F0-4794-B111-3C2E3B06E50A Q26778659-E66C82EA-B702-4D39-949F-049BFA84A9E7 Q27012532-22D99CB6-6EEF-461F-B135-15DE2822D7FF Q28555072-AC60EFD7-1E2A-42F0-BEC9-836EB600C133 Q33916951-B5535C97-17D9-4DCA-B0D0-121DA184D6DB Q33936131-041D9083-041D-48AD-830F-D0D79AF6E2B7 Q34181734-EC3658AE-D565-408D-BD1E-AEF1CDFE51D4 Q34682939-C1A9F6C6-AA15-4D35-80C8-7E43D2107D28 Q35091243-8E5E8C46-4CE1-4C79-B134-4572351852A8 Q35489060-DD6CB978-525D-4E75-B35C-87A627370894 Q36072140-A328056E-4A28-43F1-937C-A06EBD4C73BE Q36382379-7F5DFCD5-75EC-40E1-9AB1-AB25972F96E3 Q36400524-798E2F55-A623-41F5-9301-E69415AE0B3B Q36534150-54055C58-384B-49BE-8B31-538419E07A6B Q36570112-0DC4E78D-ADED-41A6-A720-1A80FF445A5D Q37115123-C55D6296-9EAC-4440-AEF1-38071A54143A Q37697498-45B4A927-A320-4D1E-9687-015E5756A53E Q37844891-48E7418A-8C7B-4C8C-AA35-65F45BCE3841 Q37910205-054B8AA7-2348-4981-8912-8F582BBD2827 Q37924086-3EED6AF2-C51E-454A-B087-AFAC842C3221 Q38069201-CF8FCDFA-B870-4900-A852-C95EB8144E20 Q38075519-9B3CA09B-B32E-48FE-8CC4-312E34F1620A Q38226807-42239773-E2AC-4B04-A77E-84D5B416B32B Q38241316-45224A05-96D4-4711-890B-1667986EAEAB Q38420631-C7B30C66-691D-43CC-BA90-1C6CE29452B6 Q38548311-943556F7-78F4-49E3-86B0-B3B0C42914DE Q38751315-7DC611E1-765A-4BAD-B909-0F92101E756F Q38821307-897896FB-47F8-4FE7-825B-4ABEA0AFED8B Q38822819-B2719AB7-F9A3-41B5-B47D-006718DE52BB Q38853630-AFCD04B9-4400-4074-9651-2B2F0AF8BF32 Q38969897-DFC1FA97-24BA-4377-B4DC-A5CA7CA4C4C7 Q39564664-020E759C-17BD-41DF-9A9D-B0873D77F1F7 Q39760319-FE5F7B65-9FF8-43A4-8CB9-605ECB4BFAFE Q42777572-1495AD82-09C9-4F78-BCA6-C406EB5412F3 Q43952443-8526DE54-B231-43BE-B915-CF2DA222DA24 Q46219056-66608E60-D590-4062-9066-D0736520CD67 Q47161197-00896EA9-252C-4521-901B-22FF754433AA Q49183821-0B813F50-59BB-4EDA-BA53-403C44225795

P2860

Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria

http://www.wikidata.org/entity/Q33665436

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Synergistic electrophysiologic ...... nic amiodarone in canine atria

@ast

Synergistic electrophysiologic ...... nic amiodarone in canine atria

@en

type

label

Synergistic electrophysiologic ...... nic amiodarone in canine atria

@ast

Synergistic electrophysiologic ...... nic amiodarone in canine atria

@en

prefLabel

Synergistic electrophysiologic ...... nic amiodarone in canine atria

@ast

Synergistic electrophysiologic ...... nic amiodarone in canine atria

@en

P1433

Q33665436-30F408A7-021A-4321-AFF6-F7D408509E77

P1476

Q33665436-299D6FCE-2953-418E-A9F9-B7E8D0CE5630

P2093

Q33665436-38D74B8F-907A-4A76-A616-7311474B1069

Q33665436-591403FD-6E27-44D6-9B80-2B948B7D359F

Q33665436-7490D80E-0856-4135-A7EF-EA03C3017D07

P2860

Q33665436-0F6BEB59-E8B8-4CD5-ADE2-AF04B4E8E240

Q33665436-108638C6-0BBB-4CAB-B0D6-7BB58E95043D

Q33665436-10DFFEA4-EDB4-4CFF-AE35-E71E12C7D6CB

Q33665436-135C3D82-53DE-48A7-991C-8A083BCD9065

Q33665436-15573BC5-BB0A-4131-861E-1B96EA99809F

Q33665436-1BB90DF4-6743-4F14-83EE-56809DB00DE1

Q33665436-1D4AE23C-2585-458B-B7F0-A01BFC1A297D

Q33665436-1E47A3AB-F6EA-47A4-BE3F-EEFE7387C495

Q33665436-20658C0E-7A53-4E03-9478-4D8D7FC7FC8D

Q33665436-20C5E28D-E8DF-4FFE-B2A8-50E32FDDCA46

P304

Q33665436-6C2E3B95-E33A-4C36-92FA-4DCB9EC4506E

P31

Q33665436-829591DF-4FD4-4029-985E-58133CBD9829

P356

Q33665436-23ACB765-7EBA-41E8-83C4-8F7C2C1E16E6

P433

Q33665436-69F632B4-4ECF-499A-AC17-A38D24460206

P478

Q33665436-144ABB82-2C92-4FB1-AEAE-32E6D177FA87

P50

Q33665436-88270977-947A-4398-896B-F3EA7D14560E

Q33665436-AE54CEC0-94EF-4FC1-9D32-0A2A62A15268

P577

Q33665436-D9C15750-4EED-42D2-8920-D50117ECCA13

P5875

Q33665436-36837F4F-5B93-435A-88BC-11F6E780DAB3

P698

Q33665436-7C2BE7F0-B608-4593-A8CF-613E97139D45

P932

Q33665436-7650C042-F6F6-453B-A76A-ED52D15989F7

P356

CIRCEP.109.886275

P1433

Circulation: Arrhythmia and Electrophysiology

P1476

Synergistic electrophysiologic ...... nic amiodarone in canine atria

@en

P2093

Alexander Burashnikov

http://www.w3.org/2001/XMLSchema#string

Luiz Belardinelli

http://www.w3.org/2001/XMLSchema#string

Serge Sicouri

http://www.w3.org/2001/XMLSchema#string

P2860

Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation

Clinical efficacy of amiodarone as an antiarrhythmic agent

Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins

Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current.

The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart.

Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent.

Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current

Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.

P304

88-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCEP.109.886275

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Charles Antzelevitch

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40045352

http://www.w3.org/2001/XMLSchema#string

P698

19952329

http://www.w3.org/2001/XMLSchema#string

P932

2824029

http://www.w3.org/2001/XMLSchema#string